+44.2%
EOG vs MRNA
+945.0%
-900.9%
-13.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.2% | +13.1% | -18.3% | -5.1% |
| 7D | -8.6% | +20.6% | -29.3% | -8.5% |
| 30D | +2.8% | +27.1% | -24.4% | +3.0% |
| 3M | +3.2% | +353.4% | -350.2% | +4.7% |
| 6M | +5.3% | +446.3% | -440.9% | +6.9% |
| YTD | +44.5% | +776.2% | -731.7% | +41.8% |
| 1Y | +44.2% | +987.9% | -943.8% | +37.7% |
| All | +44.2% | +945.0% | -900.9% | +37.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling